Lacosamid Aristo

Lacosamide, the active ingredient in Lacosamid Aristo, is a sodium channel blocker presented as an oral formulation for oral use. It is indicated as adjunctive therapy for focal (partial‑onset) seizures in patients with epilepsy, helping to reduce seizure frequency when added to existing antiepileptic regimens. The medication works by stabilizing neuronal membranes and is approved for use in the European Union. It is supplied in compliance with Good Distribution Practice standards.

GNH USA supplies Lacosamid Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant used in the management of focal seizures. - Focal (partial‑onset) seizures: Reduces seizure frequency as adjunctive therapy in epilepsy patients. - Partial‑onset seizures with secondary generalization: Provides additional seizure control when added to existing regimens. - Epilepsy adjunctive treatment: Enhances overall seizure management in patients already on antiepileptic drugs.

Adverse reactions may occur with lacosamide therapy.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome

Before initiating therapy, consider the following precautions. - Dose adjustment in renal impairment: Reduce dose according to renal function. - Monitor cardiac conduction: Baseline ECG recommended. - Assess for suicidal behavior: Regular psychiatric evaluation. - Avoid abrupt discontinuation: Taper under medical supervision. - Pregnancy and lactation: Use only if benefit outweighs risk; data limited. - Store at ambient temperature: Keep below 25 °C, protect from moisture and light.

Lacosamide may interact with several medicines.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May reduce lacosamide levels. - Co‑administration with drugs that prolong PR interval (e.g., class Ia antiarrhythmics): May increase risk of cardiac conduction delay. - Concurrent use with other sodium channel blockers (e.g., lamotrigine): May increase adverse‑effect risk.

Moderate Interactions (Monitor Closely): - Combination with other antiepileptic drugs (e.g., valproate): May require dose adjustments. - Use with alcohol: May enhance central nervous system depression. - Concurrent use with hormonal contraceptives: May slightly reduce efficacy.